JAMA: 2006-06-21, Vol. 295, No. 23, Author in the Room Audio Interview

Interview with Victor G. Vogel, MD, MHS, author of Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes , published in the June 21 issue of JAMA, the Journal of the American Medical Association. Summary Points: 1. Raloxifene is as effective in reducing the risk of invasive breast cancer in postmenopausal women who are at increased risk of the disease. 2. The safety profile of raloxifene is more favorable than tamoxifen with fewer hysterectomies, uterine malignancies, serious thrombotic events, and cataracts. 3. Both physicians and patients are familiar with raloxifene and its use for preventing and treating osteoporosis, and there is a long experience with its use in healthy women.